Wolff Wiese Magana LLC Has $263,000 Stake in Novo Nordisk A/S (NYSE:NVO)

Wolff Wiese Magana LLC raised its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 25,350.0% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 3,054 shares of the company's stock after acquiring an additional 3,042 shares during the period. Wolff Wiese Magana LLC's holdings in Novo Nordisk A/S were worth $263,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the company. Novare Capital Management LLC boosted its position in Novo Nordisk A/S by 3.2% during the third quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock valued at $325,000 after purchasing an additional 85 shares during the last quarter. Steel Grove Capital Advisors LLC raised its stake in shares of Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after purchasing an additional 86 shares in the last quarter. Benjamin Edwards Inc. boosted its holdings in shares of Novo Nordisk A/S by 2.6% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company's stock valued at $493,000 after buying an additional 87 shares during the last quarter. Rosenberg Matthew Hamilton grew its stake in shares of Novo Nordisk A/S by 2.5% in the third quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company's stock valued at $454,000 after buying an additional 94 shares in the last quarter. Finally, Burns J W & Co. Inc. NY increased its holdings in Novo Nordisk A/S by 1.9% during the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company's stock worth $647,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Novo Nordisk A/S Stock Performance

NVO traded up $1.81 during trading on Wednesday, hitting $82.99. The stock had a trading volume of 8,841,867 shares, compared to its average volume of 8,274,147. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The company has a 50 day moving average price of $99.26 and a 200-day moving average price of $118.18. Novo Nordisk A/S has a one year low of $80.05 and a one year high of $148.15. The firm has a market cap of $372.42 billion, a price-to-earnings ratio of 26.86, a P/E/G ratio of 1.37 and a beta of 0.45.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research note on Monday, December 23rd. Finally, BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S has an average rating of "Buy" and an average price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.